Stereotactic Body Radiotherapy in Bulky Hepatocellular Carcinoma with or without Portal Vein Thrombosis: A Feasibility Review in an Egyptian Cohort

被引:0
|
作者
Hegazy, Mohamed Wahba [1 ]
Attallah, Hany [2 ]
El-Shahat, Khaled M. [3 ]
Mostafa, Emad [4 ]
Yassin, Adel [3 ]
Haggag, Ibraheem [4 ]
Fathy, Talaat [5 ]
Monem, Sameh M. Abdel [5 ]
Abdelmoaty, Ahmed [5 ]
Bessar, Ahmed A. [6 ]
机构
[1] Med Coll, Dept Clin Oncol & Nucl Med, Zagazig, Egypt
[2] Int Med Ctr IMC, Dept Radiat Oncol, Cairo, Egypt
[3] Al Azhar Coll Med, Dept Clin Oncol, Cairo, Egypt
[4] Int Med Ctr, Med Radiat Phys, Cairo, Egypt
[5] Coll Med, Trop Dept, Zagazig, Egypt
[6] Coll Med, Radiol Dept, Zagazig, Egypt
关键词
Stereotactic; Hepatocellular; Portal; Veins; Thrombosis; RADIATION-THERAPY; LIVER TOXICITY;
D O I
10.30476/mejc.2023.98866.1918
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Hepatocellular carcinoma (HCC) complicated by portal vein thrombosis presents significant clinical challenges. This study aims to retrospectively assess the feasibility of stereotactic irradiation for treating bulky HCC, with or without vascular invasion. Method: In this retrospective analysis, the radiotherapy treatment plans and clinical follow-up data of 22 patients diagnosed with HCC, with or without portal vein thrombosis, were reviewed. These patients underwent stereotactic body radiation therapy (SBRT) between September 2019 and September 2022. Treatment involved administering 40-50 Gy in 5 fractions using SBRT with volumetric modulated arc therapy (VMAT)/4D-computed tomography. Descriptive statistics were utilized without the application of statistical tests. Results: The mean age of the patients was 65 years, with 77% being male. Portal vein thrombosis was present in 73% of the cases, and the average tumor size was 7.2 cm (range 5-12 cm). 59% of patients were classified as Child -Pugh B. The median follow-up duration was 8 months (range 3-36 months). At 3 months, tumor response assessments revealed that 59% of patients had a partial response and 41% had stable disease; by 6 months, 37% achieved complete response, 26% maintained a partial response, and 37% had stable condition. Failure patterns included intrahepatic failure in two patients (at 7 and 9 months) and extrahepatic loss in two others (at 6 and 10 months). Radiation -induced liver disease occurred in two patients at 9- and 11 -weeks posttreatment, respectively. Liver cancer -specific mortality was 13.6%, while non -liver cancer -specific mortality stood at 9%. The progression -free survival rate was 82%. Conclusion: SBRT via VMAT represents a highly cost-effective, non-invasive local therapy with a favorable therapeutic ratio for treating bulky HCC cases, with or without vascular invasion.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 50 条
  • [41] The Role of Radiotherapy in the Treatment of Portal Vein Thrombosis from Advanced Hepatocellular Carcinoma
    Kim, Jung Hoon
    Choi, Eun Kyung
    Do Ahn, Seung
    Lee, Sang-wook
    Shin, Seong Soo
    Choi, Wonsik
    Lim, Young-suk
    Kim, Kang Mo
    Suh, Dong Jin
    Chung, Young Wha
    Lee, Young Sang
    Won, Hyung Jin
    Kim, Jong Hoon
    RADIATION ONCOLOGY JOURNAL, 2007, 25 (03): : 170 - 176
  • [42] Outcome of transarterial chemoembolization in Egyptian patients with hepatocellular carcinoma and branch portal vein thrombosis
    Abdella H.
    Shaker M.K.
    Montasser I.F.
    Sobhi M.
    Aly H.
    Sayed A.
    Saleh S.
    El Dorry A.
    Indian Journal of Gastroenterology, 2018, 37 (2) : 127 - 132
  • [43] STEREOTACTIC BODY RADIATION THERAPY ON PORTAL VEIN TUMOR THROMBUS OF HEPATOCELLULAR CARCINOMA
    Kwon, J. H.
    Bae, S. H.
    Rha, S. E.
    Jung, S. E.
    Choi, B. O.
    Jang, H. S.
    Jang, J. W.
    Choi, J. Y.
    Yoon, S. K.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S93 - S93
  • [44] Stereotactic Body Radiotherapy for Hepatocellular Carcinoma
    McPartlin, Andrew J.
    Dawson, Laura A.
    CANCER JOURNAL, 2016, 22 (04): : 296 - 301
  • [45] Management of hepatocellular carcinoma with portal vein thrombosis
    Matthew Quirk
    Yun Hwan Kim
    Sammy Saab
    Edward Wolfgang Lee
    World Journal of Gastroenterology, 2015, 21 (12) : 3462 - 3471
  • [46] Management of hepatocellular carcinoma with portal vein thrombosis
    Quirk, Matthew
    Kim, Yun Hwan
    Saab, Sammy
    Lee, Edward Wolfgang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (12) : 3462 - 3471
  • [47] Case reports of portal vein thrombosis and bile duct stenosis after stereotactic body radiation therapy for hepatocellular carcinoma
    Takahashi, Shigeo
    Kimura, Tomoki
    Kenjo, Masahiro
    Nishibuchi, Ikuno
    Takahashi, Ippei
    Takeuchi, Yuki
    Doi, Yoshiko
    Kaneyasu, Yuko
    Murakami, Yuji
    Honda, Yoji
    Aikata, Hiroshi
    Chayama, Kazuaki
    Nagata, Yasushi
    HEPATOLOGY RESEARCH, 2014, 44 (10) : E273 - E278
  • [48] Role of Stereotactic Body Radiation Therapy in Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma: A Prospective Single Institute Experience
    Pandey, S.
    Pareek, V.
    Kumar, R.
    Gupta, A.
    Kunhiparambath, H.
    Shalimar
    Gamanagatti, S.
    Gupta, S.
    Sharma, S.
    Binjola, A.
    Kumar, R.
    Pattanaik, J.
    Praveen, D. V. S.
    Sanyal, S.
    Tanwar, M. S.
    Yadavalli, P.
    Goel, V.
    Roy, S.
    Das, N.
    Sisodiya, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E330 - E331
  • [49] Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
    Hu, Yue
    Zhou, Min
    Tang, Jing
    Li, Shuang
    Liu, Hongli
    Hu, Jianli
    Ma, Hong
    Liu, Junli
    Qin, Tingting
    Yu, Xiongjie
    Chen, Yongshun
    Peng, Jin
    Zou, Yanmei
    Zhang, Tao
    Xue, Jun
    CLINICAL CANCER RESEARCH, 2023, 29 (20) : 4088 - 4097
  • [50] Efficacy of radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis
    Tian, Q.
    Li, L.
    Zhang, F.
    Wu, X.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2024, 22 (02):